{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:46:52Z","timestamp":1793324812181,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"45","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"British Heart Foundation Intermediate Clinical Research Fellowship","award":["FS\/18\/21\/33447"],"award-info":[{"award-number":["FS\/18\/21\/33447"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To assess the ability of cardiovascular magnetic resonance (CMR) to (i) measure changes in response to chemotherapy; (ii) assess the correlation between haematological response and changes in extracellular volume (ECV); and (iii) assess the association between changes in ECV and prognosis over and above existing predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In total, 176 patients with cardiac AL amyloidosis were assessed using serial N-terminal pro-B-type natriuretic peptide (NT-proBNP), echocardiography, free light chains and CMR with T1 and ECV mapping at diagnosis and subsequently 6, 12, and 24 months after starting chemotherapy. Haematological response was graded as complete response (CR), very good partial response (VGPR), partial response (PR), or no response (NR). CMR response was graded by changes in ECV as progression (\u22650.05 increase), stable (&amp;lt;0.05 change), or regression (\u22650.05 decrease). At 6 months, CMR regression was observed in 3% (all CR\/VGPR) and CMR progression in 32% (61% in PR\/NR; 39% CR\/VGPR). After 1 year, 22% had regression (all CR\/VGPR), and 22% had progression (63% in PR\/NR; 37% CR\/VGPR). At 2 years, 38% had regression (all CR\/VGPR), and 14% had progression (80% in PR\/NR; 20% CR\/VGPR). Thirty-six (25%) patients died during follow-up (40 \u00b1 15 months); CMR response at 6 months predicted death (progression hazard ratio 3.82; 95% confidence interval 1.95\u20137.49; P &amp;lt; 0.001) and remained prognostic after adjusting for haematological response, NT-proBNP and longitudinal strain (P &amp;lt; 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cardiac amyloid deposits frequently regress following chemotherapy, but only in patients who achieve CR or VGPR. Changes in ECV predict outcome after adjusting for known predictors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehac363","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T13:03:05Z","timestamp":1661346185000},"page":"4722-4735","source":"Crossref","is-referenced-by-count":113,"title":["Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3595-6988","authenticated-orcid":false,"given":"Ana","family":"Martinez-Naharro","sequence":"first","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3177-5680","authenticated-orcid":false,"given":"Rishi","family":"Patel","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0059-4817","authenticated-orcid":false,"given":"Tushar","family":"Kotecha","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"},{"name":"Institute of Cardiovascular Science, University College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0107-7064","authenticated-orcid":false,"given":"Nina","family":"Karia","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"},{"name":"Institute of Cardiovascular Science, University College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ioannou","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5236-4741","authenticated-orcid":false,"given":"Aviva","family":"Petrie","sequence":"additional","affiliation":[{"name":"UCL Eastman Dental Institute , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza A","family":"Chacko","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4766-3293","authenticated-orcid":false,"given":"Yousuf","family":"Razvi","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5650-0088","authenticated-orcid":false,"given":"Sriram","family":"Ravichandran","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brown","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"},{"name":"Institute of Cardiovascular Science, University College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-5526","authenticated-orcid":false,"given":"Steven","family":"Law","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0935-2873","authenticated-orcid":false,"given":"Cristina","family":"Quarta","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shameem","family":"Mahmood","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Wisniowski","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pica","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajitha","family":"Sachchithanantham","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J","family":"Lachmann","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8071-1491","authenticated-orcid":false,"given":"James C","family":"Moon","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London , London , UK"},{"name":"Barts Heart Centre , West Smithfield, London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0512-3961","authenticated-orcid":false,"given":"Daniel S","family":"Knight","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"},{"name":"Institute of Cardiovascular Science, University College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Whelan","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Venneri","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-5530","authenticated-orcid":false,"given":"Hui","family":"Xue","sequence":"additional","affiliation":[{"name":"National Heart, Lung and Blood Institute, National Institutes of Health , Bethesda, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9875-6070","authenticated-orcid":false,"given":"Peter","family":"Kellman","sequence":"additional","affiliation":[{"name":"National Heart, Lung and Blood Institute, National Institutes of Health , Bethesda, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-9232","authenticated-orcid":false,"given":"Julian D","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6983-9598","authenticated-orcid":false,"given":"Philip N","family":"Hawkins","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh D","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-9831","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"2022113023531461700_ehac363-B1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","article-title":"Natural history and therapy of AL cardiac amyloidosis","volume":"20","author":"Grogan","year":"2015","journal-title":"Heart Fail Rev"},{"key":"2022113023531461700_ehac363-B2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the management of AL amyloidosis","volume":"168","author":"Wechalekar","year":"2015","journal-title":"Br J Haematol"},{"key":"2022113023531461700_ehac363-B3","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022113023531461700_ehac363-B4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/eurheartj\/ehab507","article-title":"Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis","volume":"43","author":"Cohen","year":"2022","journal-title":"Eur Heart J"},{"key":"2022113023531461700_ehac363-B5","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/eurheartj\/ehaa452","article-title":"Global longitudinal strain predicts survival and response in patients with systemic AL amyloidosis. Analysis of 915 patients from the ALchemy prospective trial [abstract]","volume":"41","author":"Cohen","year":"2020","journal-title":"Eur Heart J"},{"key":"2022113023531461700_ehac363-B6","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/leu.2016.191","article-title":"Rationale, application and clinical qualification for -proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis","volume":"30","author":"Merlini","year":"2016","journal-title":"Leukemia"},{"key":"2022113023531461700_ehac363-B7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1515\/CCLM.2004.108","article-title":"Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure","volume":"42","author":"Emdin","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"2022113023531461700_ehac363-B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","article-title":"Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study","volume":"6","author":"Banypersad","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2022113023531461700_ehac363-B9","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s10554-015-0711-1","article-title":"Impact of monitoring longitudinal systolic strain changes during serial echocardiography on outcome in patients with AL amyloidosis","volume":"31","author":"Hu","year":"2015","journal-title":"Int J Cardiovasc Imaging"},{"key":"2022113023531461700_ehac363-B10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"2022113023531461700_ehac363-B11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022113023531461700_ehac363-B12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022113023531461700_ehac363-B13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","journal-title":"Eur Heart J"},{"key":"2022113023531461700_ehac363-B14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1148\/radiol.2015141744","article-title":"Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: A cardiac MR imaging study","volume":"277","author":"Fontana","year":"2015","journal-title":"Radiology"},{"key":"2022113023531461700_ehac363-B15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022113023531461700_ehac363-B16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1148\/radiol.2016141802","article-title":"State of the art: clinical applications of cardiac T1 mapping","volume":"278","author":"Schelbert","year":"2016","journal-title":"Radiology"},{"key":"2022113023531461700_ehac363-B17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/joim.12324","article-title":"Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging","volume":"277","author":"Barison","year":"2015","journal-title":"J Intern Med"},{"key":"2022113023531461700_ehac363-B18","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/jmri.24078","article-title":"Markedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T1 mapping","volume":"38","author":"Brooks","year":"2013","journal-title":"J Magn Reson Imaging"},{"key":"2022113023531461700_ehac363-B19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1161\/CIRCIMAGING.112.973438","article-title":"T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions","volume":"5","author":"Robbers","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"2022113023531461700_ehac363-B20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022113023531461700_ehac363-B21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","article-title":"CMR-verified regression of cardiac AL amyloid after chemotherapy","volume":"11","author":"Martinez-Naharro","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022113023531461700_ehac363-B22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours France:18\u201322 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"2022113023531461700_ehac363-B23","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022113023531461700_ehac363-B24","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3324\/haematol.2019.217695","article-title":"Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria","volume":"105","author":"Sharpley","year":"2020","journal-title":"Haematologica"},{"key":"2022113023531461700_ehac363-B25","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"key":"2022113023531461700_ehac363-B26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2022113023531461700_ehac363-B27","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2022113023531461700_ehac363-B28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1532-429X-16-2","article-title":"T1-mapping in the heart: accuracy and precision","volume":"16","author":"Kellman","year":"2014","journal-title":"J Cardiovasc Magn Reson"},{"key":"2022113023531461700_ehac363-B29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1532-429X-14-88","article-title":"Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR","volume":"14","author":"Fontana","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"key":"2022113023531461700_ehac363-B30","first-page":"152","article-title":"Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials","volume":"26","author":"Gertz","year":"2012","journal-title":"Oncology"},{"key":"2022113023531461700_ehac363-B31","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"2022113023531461700_ehac363-B32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/nrneph.2013.171","article-title":"Pathophysiology and treatment of systemic amyloidosis","volume":"9","author":"Gillmore","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2022113023531461700_ehac363-B33","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJM199008233230803","article-title":"Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component","volume":"323","author":"Hawkins","year":"1990","journal-title":"N Engl J Med"},{"key":"2022113023531461700_ehac363-B34","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022113023531461700_ehac363-B35","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.4049\/jimmunol.176.11.7071","article-title":"Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera","volume":"176","author":"O\u2019Nuallain","year":"2006","journal-title":"J Immunol"},{"key":"2022113023531461700_ehac363-B36","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/45\/4722\/47466686\/ehac363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/45\/4722\/47466686\/ehac363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T18:53:36Z","timestamp":1669834416000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/45\/4722\/6650072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":36,"journal-issue":{"issue":"45","published-online":{"date-parts":[[2022,7,26]]},"published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac363","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,7,26]]}}}